AbbVie Inc. said its investigational drug upadacitinib met its primary endpoint in a phase 3 trial.
The company was evaluating the drug in patients with moderate to severe rheumatoid arthritis who did not adequately respond to prior therapy.
More than half the patients achieved a 20% improvement at week 12 of the trial, compared to 36% of patients who received placebo. Low disease activity was achieved by 48% of patients, compared to the 17% on placebo.
The drug is also being investigated to treat Crohn's disease, ulcerative colitis and atopic dermatitis.
Phase 3 trials of upadacitinib in psoriatic arthritis are also ongoing.